» Articles » PMID: 17991893

GRP78 and Cripto Form a Complex at the Cell Surface and Collaborate to Inhibit Transforming Growth Factor Beta Signaling and Enhance Cell Growth

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2007 Nov 10
PMID 17991893
Citations 97
Authors
Affiliations
Soon will be listed here.
Abstract

Cripto is a multifunctional cell surface protein with important roles in vertebrate embryogenesis and the progression of human tumors. While Cripto has been shown to modulate multiple signaling pathways, its binding partners do not appear to fully explain its molecular actions. Therefore, we conducted a screen aimed at identifying novel Cripto-interacting proteins. This screen led to our identification of glucose-regulated protein 78 (GRP78), an endoplasmic reticulum (ER) chaperone that is also expressed at the surfaces of tumor cells. Here we demonstrate that Cripto and GRP78 interact at the cell surfaces of multiple cell lines and that their interaction is independent of prior association within the ER. Interestingly, short hairpin RNA knockdown of endogenous GRP78 resulted in enhanced transforming growth factor beta (TGF-beta) signaling, indicating that like Cripto, GRP78 inhibits this pathway. We further show that when coexpressed, GRP78 and Cripto collaborate to antagonize TGF-beta responses, including Smad phosphorylation and growth inhibition of prostate cancer cells grown under anchorage-dependent or -independent conditions. Finally, we provide evidence that cells coexpressing GRP78 and Cripto grow much more rapidly in soft agar than do cells expressing either protein individually. Together, our results indicate that these proteins bind at the cell surface to enhance tumor growth via the inhibition of TGF-beta signaling.

Citing Articles

Endoplasmic Reticulum Stress: Triggers Microenvironmental Regulation and Drives Tumor Evolution.

Peng C, Wang J, Wang S, Zhao Y, Wang H, Wang Y Cancer Med. 2025; 14(5):e70684.

PMID: 40035165 PMC: 11877002. DOI: 10.1002/cam4.70684.


Diversity of extracellular HSP70 in cancer: advancing from a molecular biomarker to a novel therapeutic target.

Hu B, Liu G, Zhao K, Zhang G Front Oncol. 2024; 14:1388999.

PMID: 38646439 PMC: 11026673. DOI: 10.3389/fonc.2024.1388999.


BIRTH OF A GLYCOTHERAPY FOR BREAST CANCER.

Banerjee D Trends Carbohydr Res. 2024; 15:25-37.

PMID: 38362162 PMC: 10869124.


Novel Autophagy-Related Blood Biomarkers Associated with Immune Cell Infiltration in Ankylosing Spondylitis.

Song H, Liu H, Li X, Lv B, Tang Z, Chen Q Pharmgenomics Pers Med. 2023; 16:1055-1066.

PMID: 38073713 PMC: 10710264. DOI: 10.2147/PGPM.S428035.


Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.

Wang S, Wei W, Yuan Y, Sun B, Yang D, Liu N J Transl Med. 2023; 21(1):493.

PMID: 37481592 PMC: 10362566. DOI: 10.1186/s12967-023-04330-0.


References
1.
Lee A . The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods. 2005; 35(4):373-81. DOI: 10.1016/j.ymeth.2004.10.010. View

2.
Reddy R, Mao C, Baumeister P, Austin R, Kaufman R, Lee A . Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003; 278(23):20915-24. DOI: 10.1074/jbc.M212328200. View

3.
Misra U, Deedwania R, Pizzo S . Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. J Biol Chem. 2005; 280(28):26278-86. PMC: 1201553. DOI: 10.1074/jbc.M414467200. View

4.
Gray P, Harrison C, Vale W . Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci U S A. 2003; 100(9):5193-8. PMC: 154321. DOI: 10.1073/pnas.0531290100. View

5.
Pardali K, Moustakas A . Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2006; 1775(1):21-62. DOI: 10.1016/j.bbcan.2006.06.004. View